Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
about
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisBiomarkers and prognostic factors for mesotheliomaSupplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?Establishment of anti-mesothelioma monoclonal antibodiesClinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesotheliomaInflammation in malignant mesothelioma - friend or foe?Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesotheliomaChallenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.Biomarkers and prognostic factors for malignant pleural mesothelioma.Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.Diagnosis and prognosis-review of biomarkers for mesothelioma.Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy.Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysisClinical staging of malignant pleural mesothelioma: current perspectives.Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.Response to comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'.The value of inflammatory parameters in the prognosis of malignant mesothelioma.Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
P2860
Q27022482-61FE148A-9D13-45D7-8047-ADA2A28E9EA6Q28387194-46F053EB-B011-4B4E-8529-A802CFFBC9F2Q34041728-83A1D439-F70B-4F80-ACDD-95D500916981Q34072810-B98EF8E2-808E-4A95-9FB5-2AE41B87E0ACQ36027639-21BC5BC0-4A71-4B4F-A13E-637B3E310300Q36061312-0C4DC3C0-39D4-45AC-B5FE-25D951F1AFE0Q36345736-419E8AF5-DBE5-4878-B920-54DBDCBA532FQ36671963-6A5B6678-DDBF-470C-99EE-BF680835B356Q37090789-5110981D-616C-4C25-930C-85CE7CBDCEF6Q37090803-65B0A351-08D1-4F50-B773-60E249047844Q37214250-C6A2ECF7-BEEC-4DDC-808C-329032D284F9Q38119922-1CB5CBC1-5B39-425E-90C5-846B6B238106Q38438794-BE129352-9D17-4ED6-BB62-80653D3C43BAQ38660038-7D3ADD5F-EE60-44F5-8102-00C8E4775D0AQ38814688-690FCD0A-0E0C-40B4-B3A6-258B1A71107BQ38826424-2F4A4DDA-9EAA-48B7-BED4-F4F573EDA875Q39434249-6320699D-A912-47BA-B0DD-54EAB8512C9AQ39977787-7EC70D2D-950D-446C-A2CF-BE6295DB7FB5Q40162261-36D0155E-EEA2-485E-962F-7E8C29C55A2CQ41171241-99054032-19DA-48A0-BB5A-C9472FF04CADQ41234207-900F8CEC-B187-432A-AADE-2A2F4719F0ADQ41341293-7081782D-872D-468B-8347-3D0832E51D7EQ41522440-FB0DDB31-6B9E-4B38-9BE5-FDAAF5944F25Q42000248-74F654EC-26DF-4ECF-874B-EE7D0D2B2FC5Q42585963-D89A388A-6C8A-4A5A-84DA-30EB09B13F1DQ43595658-745D25A3-B81D-4F8B-9BE4-117E46DDD45CQ43875251-58834B3E-9816-404E-A0FF-6A58FF548FD7Q44080402-BA0783E7-8F8E-4648-8422-B4A53CA1FB68Q45226201-C41FE5F7-6068-4A3B-8C37-75C32C6AD246Q51708886-760FD113-D13F-4511-9808-01721EB49B33Q51757335-ADD928D9-FED6-419C-95DE-26611C65142EQ55044812-CA747BB8-E5A6-4D45-8409-909AB0974EFA
P2860
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@ast
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@en
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@nl
type
label
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@ast
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@en
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@nl
prefLabel
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@ast
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@en
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@nl
P2093
P50
P1433
P1476
Validation of prognostic facto ...... uth Wales Dust Diseases Board.
@en
P2093
Christopher Clarke
Nick Pavlakis
Peter Corte
Stephen Clarke
Steven C Kao
P356
10.1016/J.CLLC.2012.03.011
P407
P577
2012-06-01T00:00:00Z